A Simplified Overview of World Health Organization Classification Update of Central Nervous System Tumors 2016
- PMID: 29204027
- PMCID: PMC5709890
- DOI: 10.4103/jnrp.jnrp_168_17
A Simplified Overview of World Health Organization Classification Update of Central Nervous System Tumors 2016
Abstract
After 8 years, an update of central nervous system (CNS) tumors was published in 2016 after 2007. First time ever, molecular markers along with histology have been used in classification of any tumor. Major changes are seen in glioma and medulloblastoma groups. Few entities have been added such as diffuse midline glioma, H3 K27M-mutant, RELA fusion-positive ependymoma, embryonal tumor with multilayered rosettes, C19MC-altered, and hybrid nerve sheath tumors. Few variants and patterns that no longer have diagnostic and/or biological relevance and have been deleted such as glioblastoma cerebri, protoplasmic and fibrillary astrocytoma, and cellular ependymoma. Other changes include deletion of term "primitive neuroectodermal tumor," addition of criterion of brain invasion in atypical meningioma, separation of melanotic schwannoma from other schwannoma, and combination of solitary fibrous tumors and hemangiopericytoma as one entity. There is also expansion of entities in nerve sheath tumors and hematopoietic/lymphoid tumors of the CNS. In this review article, we tried to review CNS tumors 2016 classification update in a simplified manner; comparing the differences between 2016 and 2007 CNS tumors classifications with brief description of important molecular markers and finally utility as well as challenges of this classification.
Keywords: Central nervous system tumor update; World Health Organization classification; simplified overview.
Conflict of interest statement
There are no conflicts of interest.
Similar articles
-
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.Acta Neuropathol. 2016 Jun;131(6):803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9. Acta Neuropathol. 2016. PMID: 27157931 Review.
-
The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision.Neurol Med Chir (Tokyo). 2017 Jul 15;57(7):301-311. doi: 10.2176/nmc.ra.2017-0010. Epub 2017 Jun 8. Neurol Med Chir (Tokyo). 2017. PMID: 28592714 Free PMC article. Review.
-
Primitive Neuroectodermal Tumor.2023 Aug 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 Aug 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32965836 Free Books & Documents.
-
Molecular pathology of tumors of the central nervous system.Ann Oncol. 2019 Aug 1;30(8):1265-1278. doi: 10.1093/annonc/mdz164. Ann Oncol. 2019. PMID: 31124566 Free PMC article. Review.
-
Embryonal Tumors of the Central Nervous System: From the Radiologic Pathology Archives.Radiographics. 2018 Mar-Apr;38(2):525-541. doi: 10.1148/rg.2018170182. Radiographics. 2018. PMID: 29528832 Review.
Cited by
-
Treatments associated with all-cause mortality among children with primary brain and central nervous system tumors: a retrospective cohort study from the SEER database.Transl Pediatr. 2023 Aug 30;12(8):1504-1516. doi: 10.21037/tp-23-362. Epub 2023 Aug 28. Transl Pediatr. 2023. PMID: 37692544 Free PMC article.
-
Evaluation of total oxidative stress and antioxidant capacity of brain tumour patients attending referral hospitals in Addis Ababa, 2020: a comparative cross-sectional study.Ecancermedicalscience. 2022 May 16;16:1391. doi: 10.3332/ecancer.2022.1391. eCollection 2022. Ecancermedicalscience. 2022. PMID: 35919224 Free PMC article.
-
Proteomic Analysis on Anti-Proliferative and Apoptosis Effects of Curcumin Analog, 1,5-bis(4-Hydroxy-3-Methyoxyphenyl)-1,4-Pentadiene-3-One-Treated Human Glioblastoma and Neuroblastoma Cells.Front Mol Biosci. 2021 Apr 30;8:645856. doi: 10.3389/fmolb.2021.645856. eCollection 2021. Front Mol Biosci. 2021. PMID: 33996900 Free PMC article.
-
Injectable pH Thermo-Responsive Hydrogel Scaffold for Tumoricidal Neural Stem Cell Therapy for Glioblastoma Multiforme.Pharmaceutics. 2022 Oct 20;14(10):2243. doi: 10.3390/pharmaceutics14102243. Pharmaceutics. 2022. PMID: 36297678 Free PMC article.
-
Expression of CD44 and the survival in glioma: a meta-analysis.Biosci Rep. 2020 Apr 30;40(4):BSR20200520. doi: 10.1042/BSR20200520. Biosci Rep. 2020. PMID: 32232385 Free PMC article.
References
-
- Louis DN. WHO classification and grading of tumours of central nervous system. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Branger FD, et al., editors. WHO Classification of Tumours of the Central Nervous System. 4th ed., Revised. Lyon: International Agency for Research Centre; 2016. pp. 12–3.
-
- Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of tumors of the central nervous system: A summary. Acta Neuropathol. 2016;131:803–20. - PubMed
-
- Louis DN. WHO classification of tumours of central nervous system. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Branger FD, et al., editors. WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon: International Agency for Research Centre; 2007. pp. 8–9.
-
- Grading of the Tumors of the Central Nervous System. [Last accessed on 2017 Mar 16]. Available from: https://www.en.wikipedia.org/wiki/Grading_of_the_tumors_of_the_central_n... .
-
- Louis DN, von Deimling A, Cavenee WK. Diffuse astrocytic and oligodendroglial tumours. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Branger FD, et al., editors. WHO Classification of Tumours of the Central Nervous System. 4th ed., Revised. Lyon: International Agency for Research Centre; 2016. pp. 15–56.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases